Article Details
Retrieved on: 2025-04-15 21:56:13
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article highlights Belhaven Biopharma's successful study of Nasdepi®, a dry powder epinephrine for allergic reactions and anaphylaxis, supporting its potential as a safer, cost-effective alternative to autoinjectors, aligning with tags related to allergies and respiratory issues.
Article found on: www.pharmiweb.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here